C12Y 204/01022
Lactose synthase
Official title: Lactose synthase (2.4.1.22)
C12Y204/01022 (Lactose synthase) appears on 9 US grants and 17 published applications in this corpus.
Search patents in C12Y- Granted patents
- 9
- Published applications
- 17
- Assignees
- 11
- Inventors
- 46
- Latest grant
- 17 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 3 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 2 | 2 |
| 2021 | 0 | 2 |
| 2022 | 2 | 0 |
| 2023 | 0 | 1 |
| 2024 | 2 | 4 |
| 2025 | 1 | 4 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Genetically engineered strains with reduced byproduct formation17 Feb 2026US 12,553,071 B2Dsm IP Assets B.V.
- Inhibitors of expression and/or function7 Oct 2025US 12,435,337 B2E-Therapeutics PLC
- Metabolically engineered organisms for the production of added value bio-products24 Sep 2024US 12,098,403 B2Inbiose N.V.
- Engineered and fully-functional customized glycoproteins27 Feb 2024US 11,913,051 B2Limmatech Biologics AG
- Metabolically engineered organisms for the production of added value bio-products12 Jul 2022US 11,384,374 B2Inbiose N.V.
- Cell-free enzymatic method for preparation of n-glycans25 Dec 2025US 2025/0388948 A1Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V.
- Inhibitors of expression and/or function2 Oct 2025US 2025/0304969 A1E-Therapeutics PLC
- Metabolically engineered organisms for the production of added value bio-products13 Feb 2025US 2025/0051813 A1Inbiose N.V.
- Lactose And Human Milk Oligosaccharides (HMOS) Production In Cells9 Jan 2025US 2025/0011825 A1Agency for Science, Technology and Research
- Genetically engineered strains with reduced byproduct formation12 Dec 2024US 2024/0409972 A1Dsm IP Assets B.V.
Most cited
By later US patents